Across TCGA pan-cancer cohorts, FTH1P22 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of FTH1P22’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where FTH1P22 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FTH1P22 is over-expressed in tumor, although a few such as THCA and LUSC show the opposite, repressed pattern.

KIRC, THCA, and LUSC are the cancer types where FTH1P22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FTH1P22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+1.765	<.001	11	view →
THCA	All	All	−0.578	<.001	6	view →
LUSC	All	All	−0.441	.009	6	view →
STAD	Female	All	+0.822	.018	4	view →
LIHC	Male	All	−0.279	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: FTH1P22 RNA expression & survival · all FTH1P22 data types